- Home
- JNJ vs RVPHW Comparison
JNJ vs RVPHW Comparison
Compare JNJ & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JNJ
- RVPHW
- Stock Information
- Founded
- JNJ 1886
- RVPHW N/A
- Country
- JNJ United States
- RVPHW United States
- Employees
- JNJ N/A
- RVPHW 15
- Industry
- JNJ Biotechnology: Pharmaceutical Preparations
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- JNJ Health Care
- RVPHW Health Care
- Exchange
- JNJ Nasdaq
- RVPHW Nasdaq
- Market Cap
- JNJ N/A
- RVPHW N/A
- IPO Year
- JNJ 1944
- RVPHW 2018
- Fundamental
- Price
- JNJ $155.48
- RVPHW $0.21
- Analyst Decision
- JNJ Buy
- RVPHW
- Analyst Count
- JNJ 14
- RVPHW 0
- Target Price
- JNJ $175.64
- RVPHW N/A
- AVG Volume (30 Days)
- JNJ 7.2M
- RVPHW N/A
- Earning Date
- JNJ 10-15-2024
- RVPHW N/A
- Dividend Yield
- JNJ 3.19%
- RVPHW N/A
- EPS Growth
- JNJ N/A
- RVPHW N/A
- EPS
- JNJ 6.04
- RVPHW N/A
- Revenue
- JNJ $87,696,000,000.00
- RVPHW N/A
- Revenue This Year
- JNJ $5.29
- RVPHW N/A
- Revenue Next Year
- JNJ $2.83
- RVPHW N/A
- P/E Ratio
- JNJ $25.73
- RVPHW N/A
- Revenue Growth
- JNJ 4.77
- RVPHW N/A
- 52 Week Low
- JNJ $143.13
- RVPHW N/A
- 52 Week High
- JNJ $168.85
- RVPHW N/A
- Technical
- Relative Strength Index (RSI)
- JNJ 44.27
- RVPHW N/A
- Support Level
- JNJ $151.81
- RVPHW N/A
- Resistance Level
- JNJ $155.33
- RVPHW N/A
- Average True Range (ATR)
- JNJ 2.52
- RVPHW 0.00
- MACD
- JNJ -0.06
- RVPHW 0.00
- Stochastic Oscillator
- JNJ 46.78
- RVPHW 0.00
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.